Piper Jaffray analyst Matt O’Brien kept his Overweight rating and $25 price target on Nuvectra after the company announced an immediate departure of its CEO earlier today. The analyst says the company has a “suitable replacement in Dr. Parks”, adding that while the abrupt resignation was surprising, he sees Nuvectra management as “capable of weathering the transition”.
https://thefly.com/landingPageNews.php?id=2857373
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.